Key result
In patients with the ADRβ1-389 Arg/Arg genotype, receiving low-dose beta-blockers was associated with a two-fold increased risk of death compared to high-dose therapy (HR 2.09; P=0.015).
Authors
Loading...
Should not yet guide beta-blocker dosing; leaves open need for randomized validation of genotype-guided titration.
RCT (n=957)
randomized
Yes
Hazard Ratio: 2.09
p-value: p=0.015
Fiuzat et al. (2012) conducted an RCT in chronic heart failure with reduced ejection fraction (n=957). Low-dose beta-blockers vs. High-dose beta-blockers was evaluated on risk of death (HR 2.09, p=0.015). In patients with the ADRβ1-389 Arg/Arg genotype, receiving low-dose beta-blockers was associated with a two-fold increased risk of death compared to high-dose therapy (HR 2.09; P=0.015).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: